Search

Your search keyword '"Lophatananon, A"' showing total 11 results
Start Over Author "Lophatananon, A" Journal british journal of cancer
11 results on '"Lophatananon, A"'

1. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.

Author

Agarwal, D, Pineda, S, Michailidou, K, Herranz, J, Pita, G, Moreno, L, Alonso, M, Dennis, J, Wang, Q, Bolla, M, Meyer, K, Menéndez-Rodríguez, P, Hardisson, D, Mendiola, M, González-Neira, A, Lindblom, A, Margolin, S, Swerdlow, A, Orr, N, Jones, M, Matsuo, K, Ito, H, Iwata, H, Kondo, N, Hartman, M, Hui, M, Lim, W, Iau, P, Sawyer, E, Tomlinson, I, Kerin, M, Miller, N, Kang, D, Choi, J-Y, Park, S, Noh, D-Y, Hopper, J, Schmidt, D, Makalic, E, Southey, M, Teo, S, Yip, C, Sivanandan, K, Tay, W-T, Brauch, H, Brüning, T, Hamann, U, Dunning, A, Shah, M, Andrulis, I, Knight, J, Glendon, G, Tchatchou, S, Schmidt, M, Broeks, A, Rosenberg, E, vant Veer, L, Fasching, P, Renner, S, Ekici, A, Beckmann, M, Shen, C-Y, Hsiung, C-N, Yu, J-C, Hou, M-F, Blot, W, Cai, Q, Tseng, C-C, Van Den Berg, D, Stram, D, Cox, A, Brock, I, Reed, M, Muir, K, Lophatananon, A, Stewart-Brown, S, Siriwanarangsan, P, Zheng, W, Deming-Halverson, S, Shrubsole, M, Long, J, Shu, X-O, Lu, W, Gao, Y-T, Zhang, B, Radice, P, Peterlongo, P, Manoukian, S, Mariette, F, Sangrajrang, S, McKay, J, Couch, F, Toland, A, Yannoukakos, D, Fletcher, O, Johnson, N, dos Santos Silva, I, Peto, J, Marme, F, and Burwinkel, B

Subjects
Breast Neoplasms, Case-Control Studies, Female, Genetic Predisposition to Disease, Genetic Variation, Genome-Wide Association Study, Genotype, Humans, Polymorphism, Single Nucleotide, Receptor, Fibroblast Growth Factor, Type 1, Receptor, Fibroblast Growth Factor, Type 2, Receptor, Fibroblast Growth Factor, Type 3, Receptor, Fibroblast Growth Factor, Type 4, Receptor, Fibroblast Growth Factor, Type 5
Abstract

BACKGROUND: Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast Cancer Association Consortium. METHODS: Data were combined from 49 studies, including 53 835 cases and 50 156 controls, of which 89 050 (46 450 cases and 42 600 controls) were of European ancestry, 12 893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression. RESULTS: Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95% confidence interval=1.02-1.09, P=0.0020), which is substantially lower than that observed for SNPs in FGFR2. CONCLUSION: Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree observed for FGFR2.

Published
2014

2. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles

Author

Romuald Zdrojowy, Adam Gołąb, Michał Soczawa, Karol Krzystolik, Steven A. Narod, Andrzej Borkowski, Jacek Przybyła, Krzysztof Piotrowski, Dominika Wokołorczyk, B. Masojć, Janusz Menkiszak, Kenneth Muir, Aniruddh Kashyap, Tomasz Huzarski, Anna Jakubowska, Andrzej Antczak, Andrzej Sikorski, Cezary Cybulski, Jacek Gronwald, Tadeusz Dębniak, Bohdan Górski, M. Puszyński, Marcin Słojewski, Jan Lubinski, Artitaya Lophatananon, Wojciech Kluźniak, Tomasz Borkowski, Bartosz Małkiewicz, Pawel Domagala, and Marek Sosnowski

Subjects
Adult, Male, Cancer Research, Genotype, Genotyping Techniques, CHK2, Protein Serine-Threonine Kinases, NBS1, PSA, Risk Factors, NBN, Humans, Mass Screening, Medicine, Genetic Predisposition to Disease, Precision Medicine, Allele, Genotyping, CHEK2, Alleles, Early Detection of Cancer, Germ-Line Mutation, Mass screening, Aged, Aged, 80 and over, Genetics, business.industry, screening, Prostatic Neoplasms, Genetics and Genomics, Middle Aged, prostate cancer, BRCA1, Founder Effect, Checkpoint Kinase 2, Prostate cancer screening, Oncology, Personalized medicine, business, SNPs, Founder effect
Abstract

Background: To evaluate whether genotyping for 18 prostate cancer founder variants is helpful in identifying high-risk individuals and for determining optimal screening regimens. Methods: A serum PSA level was measured and a digital rectal examination (DRE) was performed on 2907 unaffected men aged 40–90. Three hundred and twenty-three men with an elevated PSA (⩾4 ng ml−1) or an abnormal DRE underwent a prostate biopsy. All men were genotyped for three founder alleles in BRCA1 (5382insC, 4153delA and C61G), for four alleles in CHEK2 (1100delC, IVS2+1G>A, del5395 and I157T), for one allele in NBS1 (657del5), for one allele in HOXB13 (G84E), and for nine low-risk single-nucleotide polymorphisms (SNPs). Results: On the basis of an elevated PSA or an abnormal DRE, prostate cancer was diagnosed in 135 of 2907 men (4.6%). In men with a CHEK2 missense mutation I157T, the cancer detection rate among men with an elevated PSA or an abnormal DRE was much higher (10.2%, P=0.0008). The cancer detection rate rose with the number of SNP risk genotypes observed from 1.2% for men with no variant to 8.6% for men who carried six or more variants (P=0.04). No single variant was helpful on its own in predicting the presence of prostate cancer, however, the combination of all rare mutations and SNPs improved predictive power (area under the curve=0.59; P=0.03). Conclusion: These results suggest that testing for germline CHEK2 mutations improves the ability to predict the presence of prostate cancer in screened men, however, the clinical utility of incorporating DNA variants in the screening process is marginal.

Published
2013

3. Diagnostic radiation procedures and risk of prostate cancer

Author

Polyxeni Dimitropoulou, Amanda L. Hall, Lynne T. O'Brien, Timothy J. Key, Puja R. Myles, S. Evans, Richard Pocock, Rosemary A. Wilkinson, Michelle Guy, B. Gehr-Swain, David P. Dearnaley, Douglas F. Easton, S. Edwards, Kenneth Muir, Rosalind A. Eeles, and Artitaya Lophatananon

Subjects
Male, Cancer Research, medicine.medical_specialty, Neoplasms, Radiation-Induced, Epidemiology, Prostate cancer, Risk Factors, Prostate, Internal medicine, case–control, medicine, Humans, Genetic Predisposition to Disease, Risk factor, Family history, Barium enema, Gynecology, prostate, business.industry, Prostatic Neoplasms, Cancer, Dose-Response Relationship, Radiation, Urography, Odds ratio, Middle Aged, medicine.disease, Barium meal, radiation, Radiography, medicine.anatomical_structure, Oncology, Case-Control Studies, business
Abstract

Exposure to ionising radiation is an established risk factor for many cancers. We conducted a case-control study to investigate whether exposure to low dose ionisation radiation from diagnostic x-ray procedures could be established as a risk factor for prostate cancer. In all 431 young-onset prostate cancer cases and 409 controls frequency matched by age were included. Exposures to barium meal, barium enema, hip x-rays, leg x-rays and intravenous pyelogram (IVP) were considered. Exposures to barium enema (adjusted odds ratio (OR) 2.06, 95% confidence interval (CI) 1.01-4.20) and hip x-rays (adjusted OR 2.23, 95% CI 1.42-3.49) at least 5 years before diagnosis were significantly associated with increased prostate cancer. For those with a family history of cancer, exposures to hip x-rays dating 10 or 20 years before diagnosis were associated with a significantly increased risk of prostate cancer: adjusted OR 5.01, 95% CI 1.64-15.31 and adjusted OR 14.23, 95% CI 1.83-110.74, respectively. Our findings show that exposure of the prostate gland to diagnostic radiological procedures may be associated with increased cancer risk. This effect seems to be modified by a positive family history of cancer suggesting that genetic factors may play a role in this risk association.

Published
2008

4. Hand pattern indicates prostate cancer risk

Author

Amanda L. Hall, Jo-Fen Liu, Elizabeth Page, Douglas F. Easton, Terence L. Parker, David P. Dearnaley, Kenneth Muir, Richard Pocock, Rosemary A. Wilkinson, Michelle Guy, John Anderson, Lynne T. O'Brien, Aneela Atta Ur Rahman, Zsofia Kote-Jarai, D. Harriss, Artitaya Lophatananon, Rosalind A. Eeles, Sarah Stewart-Brown, and Elinor Sawyer

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Short Communication, hand pattern, Population, Urology, Lower risk, Fingers, Prostate cancer, Risk Factors, medicine, Ring finger, Humans, education, Letter to the Editor, Aged, Aged, 80 and over, Gynecology, education.field_of_study, business.industry, Case-control study, Prostatic Neoplasms, case–control study, Index finger, Odds ratio, Middle Aged, prostate cancer, Hand, medicine.disease, Confidence interval, medicine.anatomical_structure, Oncology, Case-Control Studies, business
Abstract

Background: The ratio of digit lengths is fixed in utero, and may be a proxy indicator for prenatal testosterone levels. Methods: We analysed the right-hand pattern and prostate cancer risk in 1524 prostate cancer cases and 3044 population-based controls. Results: Compared with index finger shorter than ring finger (low 2D : 4D), men with index finger longer than ring finger (high 2D : 4D) showed a negative association, suggesting a protective effect with a 33% risk reduction (odds ratio (OR) 0.67, 95% confidence interval (CI) 0.57–0.80). Risk reduction was even greater (87%) in age group

Published
2010

6. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Author

Lophatananon, Artitaya, Stewart-Brown, Sarah, Kote-Jarai, Zsofia, Olama, Ali Amin Al, Garcia, Sara Benlloch, Neal, David E, Hamdy, Freddie C, Donovan, Jenny L, Giles, Graham G, Fitzgerald, Liesel M, Southey, Melissa C, Pharoah, Paul, Pashayan, Nora, Gronberg, Henrik, Wiklund, Fredrik, Aly, Markus, Stanford, Janet L, Brenner, Hermann, Dieffenbach, Aida K, and Arndt, Volker

Subjects
*GENETIC polymorphisms, *PROSTATE tumors, *RESEARCH funding, *RISK assessment, *STATURE, *PHENOTYPES, *CASE-control method, *TUMOR grading
Abstract

Background: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.Methods: We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.Results: The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.Conclusions: There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

7. Diagnostic radiation procedures and risk of prostate cancer

Author

Myles, P, primary, Evans, S, additional, Lophatananon, A, additional, Dimitropoulou, P, additional, Easton, D, additional, Key, T, additional, Pocock, R, additional, Dearnaley, D, additional, Guy, M, additional, Edwards, S, additional, O'Brien, L, additional, Gehr-Swain, B, additional, Hall, A, additional, Wilkinson, R, additional, Eeles, R, additional, and Muir, K, additional

Published
2008
Full Text
View/download PDF

8. Hand pattern indicates prostate cancer risk.

Author

Rahman, A. A., Lophatananon, A., Stewart-Brown, S., Harriss, D., Anderson, J., Parker, T., Easton, D., Kote-Jarai, Z., Pocock, R., Dearnaley, D., Guy, M., O'Brien, L., Wilkinson, R. A., Hall, A. L., Sawyer, E., Page, E., Liu, J.-F., Eeles, R. A., Muir, K., and UK Genetic Prostate Cancer Study Collaborators

Subjects
*PROSTATE cancer, *MALE reproductive organs, *CANCER patients, *TUMORS, *PATHOLOGY, *HAND physiology, *FINGERS, *COMPARATIVE studies, *RESEARCH methodology, *MEDICAL cooperation, *PROSTATE tumors, *RESEARCH, *EVALUATION research, *CASE-control method, *DIAGNOSIS, *ANATOMY
Abstract

Background: The ratio of digit lengths is fixed in utero, and may be a proxy indicator for prenatal testosterone levels.Methods: We analysed the right-hand pattern and prostate cancer risk in 1524 prostate cancer cases and 3044 population-based controls.Results: Compared with index finger shorter than ring finger (low 2D : 4D), men with index finger longer than ring finger (high 2D : 4D) showed a negative association, suggesting a protective effect with a 33% risk reduction (odds ratio (OR) 0.67, 95% confidence interval (CI) 0.57-0.80). Risk reduction was even greater (87%) in age group <60 (OR 0.13, 95% CI 0.09-0.21).Conclusion: Pattern of finger lengths may be a simple marker of prostate cancer risk, with length of 2D greater than 4D suggestive of lower risk. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

9. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Author

Lophatananon, Artitaya, Stewart-Brown, Sarah, Kote-Jarai, Zsofia, Al Olama, Ali Amin, Garcia, Sara Benlloch, Neal, David E, Hamdy, Freddie C, Donovan, Jenny L, Giles, Graham G, Fitzgerald, Liesel M, Southey, Melissa C, Pharoah, Paul, Pashayan, Nora, Gronberg, Henrik, Wiklund, Fredrik, Aly, Markus, Stanford, Janet L, Brenner, Hermann, Dieffenbach, Aida K, and Arndt, Volker

Abstract

This corrects the article DOI: 10.1038/bjc.2017.231. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

10. Reply: 'Hand pattern indicates risk of prostate cancer'.

Author

Rahman, A. A., Lophatananon, A., Stewart-Brown, S., Harriss, D., Anderson, J., Parker, T., Easton, D., Kote-Jarai, Z., Pocock, R., Dearnaley, D., Guy, M., O'Brien, L., Wilkinson, R. A., Hall, A. L., Sawyer, E., Page, E., Liu, J.-F., Eeles, R. A., and Muir, K.-R.

Subjects
*LETTERS to the editor, *PROSTATE diseases
Abstract

A letter to the editor is presented in response to the article "Hand pattern indicates risk of prostate cancer," by M. Cheema and A. Sharif in the 2011 issue.

Published
2011
Full Text
View/download PDF

11. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.

Author

Cybulski C, Wokołorczyk D, Kluźniak W, Kashyap A, Gołąb A, Słojewski M, Sikorski A, Puszyński M, Soczawa M, Borkowski T, Borkowski A, Antczak A, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Domagała P, Piotrowski K, Menkiszak J, Krzystolik K, Gronwald J, Jakubowska A, Górski B, Dębniak T, Masojć B, Huzarski T, Muir KR, Lophatananon A, Lubiński J, and Narod SA

Subjects
Adult, Aged, Aged, 80 and over, Alleles, Checkpoint Kinase 2, Genetic Predisposition to Disease genetics, Genotype, Humans, Male, Mass Screening methods, Middle Aged, Precision Medicine methods, Prostatic Neoplasms genetics, Risk Factors, Early Detection of Cancer methods, Founder Effect, Genotyping Techniques, Germ-Line Mutation, Prostatic Neoplasms diagnosis, Protein Serine-Threonine Kinases genetics
Abstract

Background: To evaluate whether genotyping for 18 prostate cancer founder variants is helpful in identifying high-risk individuals and for determining optimal screening regimens., Methods: A serum PSA level was measured and a digital rectal examination (DRE) was performed on 2907 unaffected men aged 40-90. Three hundred and twenty-three men with an elevated PSA (≥4 ng ml⁻¹) or an abnormal DRE underwent a prostate biopsy. All men were genotyped for three founder alleles in BRCA1 (5382insC, 4153delA and C61G), for four alleles in CHEK2 (1100delC, IVS2+1G>A, del5395 and I157T), for one allele in NBS1 (657del5), for one allele in HOXB13 (G84E), and for nine low-risk single-nucleotide polymorphisms (SNPs)., Results: On the basis of an elevated PSA or an abnormal DRE, prostate cancer was diagnosed in 135 of 2907 men (4.6%). In men with a CHEK2 missense mutation I157T, the cancer detection rate among men with an elevated PSA or an abnormal DRE was much higher (10.2%, P=0.0008). The cancer detection rate rose with the number of SNP risk genotypes observed from 1.2% for men with no variant to 8.6% for men who carried six or more variants (P=0.04). No single variant was helpful on its own in predicting the presence of prostate cancer, however, the combination of all rare mutations and SNPs improved predictive power (area under the curve=0.59; P=0.03)., Conclusion: These results suggest that testing for germline CHEK2 mutations improves the ability to predict the presence of prostate cancer in screened men, however, the clinical utility of incorporating DNA variants in the screening process is marginal.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results